|
US3710795A
(en)
|
1970-09-29 |
1973-01-16 |
Alza Corp |
Drug-delivery device with stretched, rate-controlling membrane
|
|
US4485045A
(en)
|
1981-07-06 |
1984-11-27 |
Research Corporation |
Synthetic phosphatidyl cholines useful in forming liposomes
|
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
|
US4544545A
(en)
|
1983-06-20 |
1985-10-01 |
Trustees University Of Massachusetts |
Liposomes containing modified cholesterol for organ targeting
|
|
IL79289A
(en)
|
1985-07-05 |
1992-01-15 |
Whitehead Biomedical Inst |
Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus
|
|
US4980286A
(en)
|
1985-07-05 |
1990-12-25 |
Whitehead Institute For Biomedical Research |
In vivo introduction and expression of foreign genetic material in epithelial cells
|
|
US4863457A
(en)
|
1986-11-24 |
1989-09-05 |
Lee David A |
Drug delivery device
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・２・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
ATE117375T1
(de)
|
1987-09-11 |
1995-02-15 |
Whitehead Biomedical Inst |
Transduktionsveränderte fibroblasten und ihre anwendung.
|
|
JP2914692B2
(ja)
|
1987-12-11 |
1999-07-05 |
ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ |
内皮細胞の遺伝子修飾
|
|
WO1989007136A2
(en)
|
1988-02-05 |
1989-08-10 |
Whitehead Institute For Biomedical Research |
Modified hepatocytes and uses therefor
|
|
US5013556A
(en)
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
|
US5164188A
(en)
|
1989-11-22 |
1992-11-17 |
Visionex, Inc. |
Biodegradable ocular implants
|
|
ES2096750T3
(es)
|
1990-10-31 |
1997-03-16 |
Somatix Therapy Corp |
Vectores retroviricos utiles para la terapia genica.
|
|
KR0185215B1
(ko)
|
1990-11-30 |
1999-05-01 |
요시다 쇼오지 |
서방성 안구삽입용 약제
|
|
US5714350A
(en)
|
1992-03-09 |
1998-02-03 |
Protein Design Labs, Inc. |
Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
|
|
CA2137667A1
(en)
|
1992-07-23 |
1994-02-03 |
Todd A. Berg |
Shaped abrasive particles and method of making same
|
|
US6005079A
(en)
|
1992-08-21 |
1999-12-21 |
Vrije Universiteit Brussels |
Immunoglobulins devoid of light chains
|
|
DK1621554T4
(da)
|
1992-08-21 |
2012-12-17 |
Univ Bruxelles |
Immunoglobuliner blottet for lette kæder
|
|
US5885573A
(en)
|
1993-06-01 |
1999-03-23 |
Arch Development Corporation |
Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
|
|
IT1265573B1
(it)
|
1993-09-17 |
1996-11-22 |
Zanussi Grandi Impianti Spa |
Forno di cottura di alimenti con porta perfezionata
|
|
US5308341A
(en)
|
1993-09-28 |
1994-05-03 |
Becton, Dickinson And Company |
Method of testing the dose accuracy of a medication delivery device
|
|
US5443505A
(en)
|
1993-11-15 |
1995-08-22 |
Oculex Pharmaceuticals, Inc. |
Biocompatible ocular implants
|
|
ATE416755T1
(de)
|
1994-03-07 |
2008-12-15 |
Nektar Therapeutics |
Verfahren und zusammensetzung für die pulmonale darreichung von insulin
|
|
US6074642A
(en)
|
1994-05-02 |
2000-06-13 |
Alexion Pharmaceuticals, Inc. |
Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
|
|
US6019968A
(en)
|
1995-04-14 |
2000-02-01 |
Inhale Therapeutic Systems, Inc. |
Dispersible antibody compositions and methods for their preparation and use
|
|
ES2176484T3
(es)
|
1995-08-18 |
2002-12-01 |
Morphosys Ag |
Bancos de proteinas/(poli)peptidos.
|
|
US5773019A
(en)
|
1995-09-27 |
1998-06-30 |
The University Of Kentucky Research Foundation |
Implantable controlled release device to deliver drugs directly to an internal portion of the body
|
|
JP4046354B2
(ja)
|
1996-03-18 |
2008-02-13 |
ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム |
増大した半減期を有する免疫グロブリン様ドメイン
|
|
US6001329A
(en)
|
1996-05-06 |
1999-12-14 |
Uab Research Foundation |
Radiolabeled fusion toxins for cancer therapy
|
|
US6146361A
(en)
|
1996-09-26 |
2000-11-14 |
Becton Dickinson And Company |
Medication delivery pen having a 31 gauge needle
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
GB9626960D0
(en)
|
1996-12-27 |
1997-02-12 |
Glaxo Group Ltd |
Valve for aerosol container
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
WO1998047531A2
(en)
|
1997-04-21 |
1998-10-29 |
Arch Development Corporation |
Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
|
|
US5954047A
(en)
|
1997-10-17 |
1999-09-21 |
Systemic Pulmonary Development, Ltd. |
Methods and apparatus for delivering aerosolized medication
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
US6302855B1
(en)
|
1998-05-20 |
2001-10-16 |
Novo Nordisk A/S |
Medical apparatus for use by a patient for medical self treatment of diabetes
|
|
PL209392B1
(pl)
|
1999-01-15 |
2011-08-31 |
Genentech Inc |
Przeciwciało, komórka gospodarza, sposób wytwarzania przeciwciała oraz zastosowanie przeciwciała
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
JP2002541213A
(ja)
|
1999-04-13 |
2002-12-03 |
インヘール セラピューティック システムズ， インコーポレイテッド |
不妊症の処置のための乾燥粉末処方物の肺投与
|
|
WO2000061178A1
(en)
|
1999-04-13 |
2000-10-19 |
Inhale Therapeutics Systems, Inc. |
Pulmonary administration of dry powder formulations for treating infertility
|
|
US6192891B1
(en)
|
1999-04-26 |
2001-02-27 |
Becton Dickinson And Company |
Integrated system including medication delivery pen, blood monitoring device, and lancer
|
|
GB9910975D0
(en)
|
1999-05-13 |
1999-07-14 |
Univ Strathclyde |
Rapid dehydration of proteins
|
|
US6277099B1
(en)
|
1999-08-06 |
2001-08-21 |
Becton, Dickinson And Company |
Medication delivery pen
|
|
PE20011227A1
(es)
|
2000-04-17 |
2002-01-07 |
Chiesi Farma Spa |
Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
|
|
DE60135352D1
(de)
|
2000-08-30 |
2008-09-25 |
Univ Johns Hopkins |
Vorrichtung zur intraokularen wirkstoffverabreichung
|
|
US7083784B2
(en)
|
2000-12-12 |
2006-08-01 |
Medimmune, Inc. |
Molecules with extended half-lives, compositions and uses thereof
|
|
WO2003022330A2
(en)
|
2001-09-12 |
2003-03-20 |
Becton, Dickinson And Company |
Microneedle-based pen device for drug delivery and method for using same
|
|
AU2003217912A1
(en)
|
2002-03-01 |
2003-09-16 |
Xencor |
Antibody optimization
|
|
US20060141456A1
(en)
|
2002-06-12 |
2006-06-29 |
Cynthia Edwards |
Methods and compositions for milieu-dependent binding of a targeted agent to a target
|
|
US9415102B2
(en)
|
2002-09-06 |
2016-08-16 |
Alexion Pharmaceuticals, Inc. |
High concentration formulations of anti-C5 antibodies
|
|
US20050271660A1
(en)
|
2002-09-06 |
2005-12-08 |
Alexion Pharmaceuticals, Inc. |
Nebulization of monoclonal antibodies for treating pulmonary diseases
|
|
US20040102469A1
(en)
|
2002-09-13 |
2004-05-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Method for reducing the mortality rate
|
|
GB0222023D0
(en)
|
2002-09-21 |
2002-10-30 |
Aventis Pharma Ltd |
Inhaler
|
|
EP1553975B8
(en)
|
2002-09-27 |
2023-04-12 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
FR2849436B1
(fr)
|
2002-12-27 |
2007-01-05 |
Patrick Frayssinet |
Particules et ceramiques de phosphates de calcium pour transfection in vivo et in vitro
|
|
US20060167435A1
(en)
|
2003-02-18 |
2006-07-27 |
Adamis Anthony P |
Transscleral drug delivery device and related methods
|
|
EP1648511A1
(en)
|
2003-07-29 |
2006-04-26 |
Morphotek, Inc. |
Antibodies and methods for generating genetically altered antibodies with enhanced effector function
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
EP1737890A2
(en)
|
2004-03-24 |
2007-01-03 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
US8685435B2
(en)
|
2004-04-30 |
2014-04-01 |
Allergan, Inc. |
Extended release biodegradable ocular implants
|
|
US7919094B2
(en)
|
2004-06-10 |
2011-04-05 |
Omeros Corporation |
Methods for treating conditions associated with MASP-2 dependent complement activation
|
|
GB0416328D0
(en)
|
2004-07-21 |
2004-08-25 |
Univ Cardiff |
Use of dry powder compositions for pulmonary delivery
|
|
US20060074225A1
(en)
|
2004-09-14 |
2006-04-06 |
Xencor, Inc. |
Monomeric immunoglobulin Fc domains
|
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
AU2005304624B2
(en)
|
2004-11-12 |
2010-10-07 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
|
US20060234303A1
(en)
|
2005-03-03 |
2006-10-19 |
Xencor, Inc. |
Methods for the design of libraries of protein variants
|
|
WO2006105338A2
(en)
|
2005-03-31 |
2006-10-05 |
Xencor, Inc. |
Fc VARIANTS WITH OPTIMIZED PROPERTIES
|
|
WO2007041635A2
(en)
|
2005-10-03 |
2007-04-12 |
Xencor, Inc. |
Fc variants with optimized fc receptor binding properties
|
|
BRPI0620316A2
(pt)
|
2005-12-21 |
2011-11-08 |
Wyeth Corp |
formulações de proteìnas com viscosidades reduzida e seus usos
|
|
JP5722524B2
(ja)
|
2006-03-02 |
2015-05-20 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
補体活性を抑制することによる同種移植片の生存の延長
|
|
US20090220508A1
(en)
|
2006-03-15 |
2009-09-03 |
Alexion Pharmaceuticals, Inc. |
Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
|
|
CN104761637B
(zh)
|
2006-03-31 |
2021-10-15 |
中外制药株式会社 |
调控抗体血液动力学的方法
|
|
US8037880B2
(en)
|
2006-04-07 |
2011-10-18 |
The University Of Western Ontario |
Dry powder inhaler
|
|
US20100034194A1
(en)
|
2006-10-11 |
2010-02-11 |
Siemens Communications Inc. |
Eliminating unreachable subscribers in voice-over-ip networks
|
|
AU2007313300A1
(en)
|
2006-10-16 |
2008-04-24 |
Medimmune, Llc. |
Molecules with reduced half-lives, compositions and uses thereof
|
|
WO2008092117A2
(en)
|
2007-01-25 |
2008-07-31 |
Xencor, Inc. |
Immunoglobulins with modifications in the fcr binding region
|
|
JP2010533181A
(ja)
|
2007-07-13 |
2010-10-21 |
アボツト・バイオテクノロジー・リミテツド |
ＴＮＦα阻害剤の肺投与のための方法及び組成物
|
|
ES2595638T3
(es)
|
2007-09-26 |
2017-01-02 |
Chugai Seiyaku Kabushiki Kaisha |
Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR
|
|
HRP20150279T1
(hr)
|
2007-12-26 |
2015-05-08 |
Xencor, Inc. |
Fc inaäśice s promijenjenim vezanjem na fcrn
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
PY09026846A
(es)
|
2008-08-05 |
2015-09-01 |
Novartis Ag |
Composiciones y métodos para anticuerpos que se dirigen a la proteína de complemento c5
|
|
JP5913980B2
(ja)
|
2008-10-14 |
2016-05-11 |
ジェネンテック， インコーポレイテッド |
免疫グロブリン変異体及びその用途
|
|
AU2015227544B2
(en)
|
2008-11-10 |
2017-05-25 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
CA2742802C
(en)
|
2008-11-10 |
2019-11-26 |
Alexion Pharmaceuticals, Inc. |
Methods and compositions for treating complement-associated disorders
|
|
CA2766565A1
(en)
|
2009-06-23 |
2010-12-29 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
|
JP5932670B2
(ja)
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
ｐＨ依存性の抗原結合を有する抗体
|
|
TWI667257B
(zh)
|
2010-03-30 |
2019-08-01 |
中外製藥股份有限公司 |
促進抗原消失之具有經修飾的ＦｃＲｎ親和力之抗體
|
|
BR112012027917A2
(pt)
|
2010-04-30 |
2017-11-28 |
Alexion Pharma Inc |
anticorpos que apresentam reduzida imunogenicidade em um indivíduo humano
|
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
|
TW201817744A
(zh)
|
2011-09-30 |
2018-05-16 |
日商中外製藥股份有限公司 |
具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
|
|
JP6322411B2
(ja)
|
2011-09-30 |
2018-05-09 |
中外製薬株式会社 |
複数の生理活性を有する抗原の消失を促進する抗原結合分子
|
|
SI3011345T1
(sl)
*
|
2013-08-07 |
2017-12-29 |
Alexion Pharmaceuticals, Inc. |
Biomarkerski proteini za atipični hemolitični uremični sindrom (ahus)
|
|
NZ631007A
(en)
|
2014-03-07 |
2015-10-30 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
BR112017011235A2
(pt)
|
2014-12-19 |
2018-02-06 |
Chugai Pharmaceutical Co Ltd |
anticorpos anti-c5 e métodos de uso
|
|
US20190135903A1
(en)
|
2015-03-31 |
2019-05-09 |
Alexion Pharmaceuticals, Inc. |
Identifying and treating subpopulations of paroxysmal nocturnal hemoglobinuria (pnh) patients
|
|
US20180311299A1
(en)
|
2015-05-01 |
2018-11-01 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
EP3313437A1
(en)
|
2015-06-26 |
2018-05-02 |
Alexion Pharmaceuticals, Inc. |
A method for treating a patient in compliance with vaccination with eculizumab or an eculizumab variant
|
|
US20170073399A1
(en)
*
|
2015-09-11 |
2017-03-16 |
Alexion Pharmaceuticals, Inc. |
Recombinant glycosylated eculizumab and eculizumab variants
|
|
JP7221691B2
(ja)
|
2015-10-30 |
2023-02-14 |
アレクシオン ファーマシューティカルズ， インコーポレイテッド |
Ｔ細胞媒介性同種移植片血管障害の増悪を抑制する方法
|
|
EP3402816A1
(en)
*
|
2016-01-11 |
2018-11-21 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment
|
|
CN116769024A
(zh)
|
2016-06-14 |
2023-09-19 |
瑞泽恩制药公司 |
抗c5抗体及其用途
|
|
WO2018071624A1
(en)
|
2016-10-12 |
2018-04-19 |
Alexion Pharmaceuticals, Inc. |
Efficacy of an anti-c5 antibody in the prevention of antibody mediated rejection in sensitized recipients of a kidney transplant
|
|
KR102365871B1
(ko)
|
2017-01-31 |
2022-02-21 |
추가이 세이야쿠 가부시키가이샤 |
C5-관련 질환의 치료 또는 예방용 의약 조성물 및 c5-관련 질환을 치료 또는 예방하기 위한 방법
|
|
DK3658184T5
(da)
|
2017-07-27 |
2024-08-26 |
Alexion Pharma Inc |
Højkoncentrerede anti-c5-antistofformuleringer
|
|
CN118512588A
(zh)
*
|
2017-10-26 |
2024-08-20 |
亚力兄制药公司 |
用于治疗阵发性夜间性血红蛋白尿(pnh)和非典型溶血性尿毒症综合征(ahus)的抗c5抗体的剂量和施用
|
|
CN111683672A
(zh)
|
2017-12-04 |
2020-09-18 |
Ra制药公司 |
补体活性调节剂
|
|
EP3802593B1
(en)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
|
|
EP3802603A1
(en)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
|
|
EP3873602B1
(en)
|
2018-10-30 |
2023-12-06 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh)
|
|
CN117838856A
(zh)
|
2019-01-25 |
2024-04-09 |
亚力兄制药公司 |
用于治疗非典型溶血性尿毒综合征(ahus)的抗c5抗体的剂量和施用
|
|
WO2021091937A1
(en)
*
|
2019-11-08 |
2021-05-14 |
Alexion Pharmaceuticals, Inc. |
High concentration anti-c5 antibody formulations
|